Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769878 | 0.93 | MEN1 (0.41) | MEN1KMT2APOLBALDH1A1TP53 | |
| SCHEMBL6767380 | 0.89 | TSHR (0.44) | MAPTGAATSHR | |
| SCHEMBL6770228 | 0.89 | MEN1 (0.42) | MEN1KMT2AALDH1A1TP53MAPK1 | |
| SCHEMBL6766054 | 0.89 | MEN1 (0.42) | MEN1KMT2APOLBALDH1A1TDP2 | |
| SCHEMBL6769778 | 0.87 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1MAPK1ATM | |
| SCHEMBL6771998 | 0.84 | FDFT1 (0.40) | MEN1KMT2APOLBALDH1A1MAPK1 | |
| SCHEMBL6945548 | 0.83 | MEN1 (0.38) | MEN1KMT2APOLBALDH1A1KCNT1 | |
| SCHEMBL6770762 | 0.82 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1MAPK1GAA | |
| SCHEMBL6769637 | 0.82 | — | — | |
| SCHEMBL6766316 | 0.82 | MAPK1 (0.38) | MEN1KMT2APOLBALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699877-B2 | TREATING PAIN, MIGRAINE, AND VARIOUS OTHER DISEASES | GRUENENTHAL GMBH (DE) | 2004-03-02 | — | — | US | disclosed |
| US-20030087926-A1 | Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives | GRUENENTHAL GMBH | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087926-A1 | Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives | SDHA, CACNA1A, GRIN2C | MEN1 416/4885KMT2A 1398/4885POLB 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.